Tetracore

Tetracore

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $34.5M

Overview

Tetracore is a long-established, commercial-stage diagnostics company specializing in assays and instruments for infectious diseases and biodefense. Its product portfolio spans lateral flow assays (LFA), real-time PCR systems, and multiplex immunoassays, targeting both human and veterinary pathogens. The company operates primarily as a B2B supplier to government, public health, and veterinary laboratories, focusing on providing actionable, on-site diagnostic solutions. Its dual focus on biothreat agents and endemic infectious diseases positions it in stable, mission-critical markets.

Infectious Disease

Technology Platform

Multi-modal diagnostics platform encompassing lateral flow immunoassays (LFA) with portable readers, real-time PCR systems (T-COR 8 thermocycler and assays), and multiplex bead-based immunoassays (FlexImmArray for Luminex systems).

Funding History

2
Total raised:$34.5M
Grant$9.8M
Grant$24.7M

Opportunities

Growth is driven by sustained biodefense funding, expansion in the high-growth veterinary diagnostics market, and the global trend towards decentralized, point-of-need testing for infectious diseases.
The company's portable platforms are well-suited for surveillance and outbreak response in low-resource settings.

Risk Factors

Key risks include dependence on U.S.
government contracting, intense competition from larger diagnostics firms, regulatory hurdles for new assays, and the niche size of the core biothreat market limiting growth potential.

Competitive Landscape

Tetracore competes with large diversified diagnostics companies (e.g., Abbott, bioMérieux, Qiagen) in infectious disease testing, and with specialized biodefense contractors (e.g., Battelle, MRIGlobal) and other niche assay developers. Its differentiation lies in its dedicated focus on biothreats and field-deployable integrated systems.